GenomeScan, a genomics service provider, has recently acquired an Illumina Novaseq™ 6000 to provide its customers with early access to world leading genomic technology. The company’s mission is to partner with hospitals and pharmaceutical companies to improve the quality of life of patients suffering from genetic disorders by developing new Next Generation Sequencing (NGS) applications.
GenomeScan acquires the novel Illumina Novaseq™ 6000 for industrial scale sequencingMonday, July 2, 2018
This instrument helps to generate more data in less time, which is especially valuable for medical specialists who urgently await their test results. The Novaseq™ 6000 can process 20 human genomes or the entire exome of up to 300 patients simultaneously, in just one day. Its performances allow GenomeScan to analyze full genomes in record time from any species, from humans to plants, bacteria and viruses.
Dr. Peter Belt, CEO of GenomeScan says: “We are the first service provider in Western-Europe to offer genetic analysis on the Novaseq™ 6000 under ISO/IEC 17025 accreditation. We can considerably decrease the turn-around time and increase the number of projects to match customer’s requirements.
Frank Baas, professor of Diagnostic Genome Analysis at the LUMC, added: “For patients with hereditary diseases, it is of the utmost importance to receive a diagnosis rapidly. GenomeScan has consistently made the latest technologies available to their customers. Their expertise and professionalism helped our laboratory to keep reducing the time for diagnosis to our patients. Five days if an urgent case is presented.”
GenomeScan is an accredited genomics service provider that develops innovative Next Generation Sequencing (NGS) applications to improve diagnosis of genetic disorders, ensure better disease risk management, and accelerate access to personalized medicine.
Our team of PhD-scientists and bioinformaticians closely works with our clients to deliver rapid and accurate reports, facilitates comprehension of large data-sets, and enables clinicians to deliver an accurate diagnosis to their patients. Learn more at www.genomescan.nl
Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy
Johnson & Johnson unveils new vaccines launch facility at Leiden Bio Science Park
Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis